Skip to main content

Advertisement

Table 3 Logistic regression models of non-persistence of DMARD

From: Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort

Variable Categories Risk of change Reasons for changing DMARD
Risk of adverse drug reaction Risk of lack of efficacy
Female gender Y/N 1.11 (0.69 - 1.80) 1.52 (0.81 – 2.85) 1.20 (0.71 – 2.03)
Age Quartiles 0.89 (0.72 - 1.10) 1.23 (0.94 – 1.60) 0.69 (0.55 – 0.87) **
Ever smoked Y/N 1.38 (0.89 - 2.15) 1.29 (0.59 – 2.78) 1.35 (0.83 – 2.19)
DAS28 EULAR categories 1.12 (0.78 - 1.62) 0.95 (0.58 – 1.57) 1.29 (0.83 – 2.02)
>4 of 1987 ACR criteria Y/N 0.98 (0.59 – 1.65) 1.04 (0.57 – 1.91) 1.20 (0.72 – 2.01)
Extra-articular disease Y/N 1.78 (1.00 - 3.16) * 1.29 (0.59 – 2.78) 2.27 (1.25 – 4.11) **
Co-morbidities Y/N 1.02 (0.66 - 1.57) 1.18 (0.67 – 2.09) 0.82 (0.51 – 1.32)
HAQ score Quartiles 1.44 (1.12 - 1.86) ** 1.10 (0.80 – 1.52) 1.36 (1.03 – 1.81) *
SF36-bodily pain Quartiles 0.93 (0.72 - 1.19) 1.03 (0.75 – 1.43) 1.18 (0.90 – 1.55)
SF36-mental health Quartiles 1.44 (1.16 - 1.78) ** 1.43 (1.08 – 1.89) * 1.22 (0.97 – 1.52)
DAS28-P Quartiles 1.09 (0.88 - 1.35) 1.04 (0.79 – 1.37) 1.10 (0.86 – 1.41)
SSZ monotherapy Y/N 1.09 (0.57 - 2.12) 1.92 (0.85 – 4.37) 0.74 (0.35 – 1.54)
MTX monotherapy Y/N 0.56 (0.29 - 1.06) 0.38 (0.16 – 0.94) * 0.57 (0.28 – 1.17)
MTX + SSZ + HCQ Y/N 0.30 (0.12 - 0.79) * 0.33 (0.08 – 1.38) 0.14 (0.04 – 0.53) **
  1. Variables associated with a non-persistence of DMARD treatment within the first 2 years in the ERAN cohort (428 people had data analysed). Adjusted odds ratios (95% confidence intervals). * = p < 0.05, ** = p < 0.01. Statistically significant results are presented in bold.